Favipiravir: A New Medication for the Ebola Virus Disease Pandemic

被引：94

作者：

Nagata, Takashi ^{[1
]}

Lefor, Alan K. ^{[2
]}

Hasegawa, Manabu ^{[3
]}

Ishii, Masami ^{[4
]}

机构：

[1] Japan Med Assoc Res Inst, Bunkyo Ku, Tokyo 1138621, Japan

[2] Jichi Med Sch, Dept Surg, Shimotsuke, Japan

[3] Shimonoseki City Publ Hlth Ctr, Shimonoseki, Yamaguchi, Japan

[4] Japan Med Assoc, Tokyo, Japan

来源：

DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS | 2015年 / 9卷 / 01期

关键词：

Anti-Infective Agents; Disease Outbreaks; Influenza; Human; T-705; FAVIPIRAVIR; MODEL; INFECTION;

D O I：

10.1017/dmp.2014.151

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The purpose of this report is to advocate speedy approval and less stringent regulations for the use of experimental drugs such as favipiravir in emergencies. Favipiravir is a new antiviral medication that can be used in emerging viral pandemics such as Ebola virus, 2009 pandemic influenza H1N1 virus, Lassa fever, and Argentine hemorrhagic fever. Although favipiravir is one of the choices for the treatment of patients with Ebola virus, several concerns exist. First, a clinical trial of favipiravir in patients infected with the Ebola virus has not yet been conducted, and further studies are required. Second, favipiravir has a risk for teratogenicity and embryotoxicity. Therefore, the Ministry of Health, Welfare and Labor of Japan has approved this medication with strict regulations for its production and clinical use. However, owing to the emerging Ebola virus epidemic in West Africa, on August 15, 2014, the Minister of Health, Welfare and Labor of Japan approved the use of favipiravir, if needed. (Disaster Med Public Health Preparedness. 2014;0:1-3)

引用

页码：79 / 81

页数：3

共 9 条

[1] Ebola Virus Disease in the Democratic Republic of Congo [J].

Maganga, Gael D. ;

Kapetshi, Jimmy ;

Berthet, Nicolas ;

Ilunga, Benoit Kebela ;

Kabange, Felix ;

Kingebeni, Placide Mbala ;

Mondonge, Vital ;

Muyembe, Jean-Jacques T. ;

Bertherat, Eric ;

Briand, Sylvie ;

Cabore, Joseph ;

Epelboin, Alain ;

Formenty, Pierre ;

Kobinger, Gary ;

Gonzalez-Angulo, Lice ;

Labouba, Ingrid ;

Manuguerra, Jean-Claude ;

Okwo-Bele, Jean-Marie ;

Dye, Christopher ;

Leroy, Eric M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (22) :2083-2091

[2] Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever [J].

Mendenhall, Michelle ;

Russell, Andrew ;

Smee, Donald F. ;

Hall, Jeffery O. ;

Skirpstunas, Ramona ;

Furuta, Yousuke ;

Gowen, Brian B. .

PLOS NEGLECTED TROPICAL DISEASES, 2011, 5 (10)

[3]

Ministry of Health Welfare and Labor Japan, 2014, SUMM MED C TAM MIN H

[4] Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model [J].

Oestereich, Lisa ;

Luedtke, Anja ;

Wurr, Stephanie ;

Rieger, Toni ;

Munoz-Fontela, Cesar ;

Guenther, Stephan .

ANTIVIRAL RESEARCH, 2014, 105 :17-21

[5] Combination Effects of Peramivir and Favipiravir against Oseltamivir-Resistant 2009 Pandemic Influenza A(H1N1) Infection in Mice [J].

Park, Sehee ;

Kim, Jin Il ;

Lee, Ilseob ;

Lee, Sangmoo ;

Hwang, Min-Woong ;

Bae, Joon-Yong ;

Heo, Jun ;

Kim, Donghwan ;

Jang, Seok-Il ;

Kim, Hyejin ;

Cheong, Hee Jin ;

Song, Jin-Won ;

Song, Ki-Joon ;

Baek, Luck Ju ;

Park, Man-Seong .

PLOS ONE, 2014, 9 (07)

[6]

Prime Minister of Japan and His Cabinet, 2014, OFF MED C CURR SIT E

[7] Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model [J].

Smither, Sophie J. ;

Eastaugh, Lin S. ;

Steward, Jackie A. ;

Nelson, Michelle ;

Lenk, Robert P. ;

Lever, Mark S. .

ANTIVIRAL RESEARCH, 2014, 104 :153-155

[8]

WHO, 2014, WHO EB RESP ROADM

[9]

World Medical Association, 2014, WMA RES UNPR THER EB

← 1 →